Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Brain : a journal of neurology

• Publication date

  1980-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/BRAIN/103.1.179PMID 6102490
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

  1998cited by this paper
• Multiple system atrophy with autonomic failure: clinical, histological and neurochemical observations on four cases.

  1979cited by this paper
• Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia.

  1979cited by this paper
• An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human post-mortem brain tissue.

  1979cited by this paper
• DIFFERENTIAL EFFECTS OF AGONAL STATUS ON MEASUREMENTS OF GABA AND GLUTAMATE DECARBOXYLASE IN HUMAN POST‐MORTEM BRAIN TISSUE FROM CONTROL AND HUNTINGTON'S CHOREA SUBJECTS

  1979cited by this paper
• Characterization of brain dopaminergic receptors in Huntington's disease.

  1978cited by this paper
• Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue.

  1977cited by this paper
• Postmortem stability of norepinephrine, dopamine, and serotonin in rat brain 1

  1977cited by this paper
• Biochemical aspects of Huntington's chorea.

  1977cited by this paper
• Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses.

  1977cited by this paper
• Immunohistochemical localization of choline acetyltransferase containing neostriatal neurons and their relationship with dopaminergic synapses.

  1976cited by this paper
• Choline in tardive dyskinesia and Huntington's disease.

  1976cited by this paper
• Alterations of brain neurotransmitter receptor binding in Huntington's chorea.

  1976cited by this paper
• Selective loss of central cholinergic neurons in Alzheimer's disease.

  1976cited by this paper
• Morphometric studies of the neuropathological changes in choreatic diseases.

  1976cited by this paper
• Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

  1976cited by this paper
• ENZYMES ASSOCIATED WITH THE METABOLISM OF CATECHOLAMINES, ACETYLCHOLINE AND GABA IN HUMAN CONTROLS AND PATIENTS WITH PARKINSON'S DISEASE AND HUNTINGTON'S CHOREA

  1976cited by this paper
• Effects of dopaminergic receptor agonists and antagonists on the activity of the neo-striatal cholinergic system.

  1975cited by this paper
• GABA CONTENT AND GLUTAMIC ACID DECARBOXYLASE ACTIVITY IN BRAIN OF HUNTINGTON'S CHOREA PATIENTS AND CONTROL SUBJECTS 1

  1975cited by this paper
• Demonstration of a pallido‐nigral projection innervating dopaminergic neurons

  1975cited by this paper
• Increase in rat brain acetylcholine induced by choline or deanol.

  1975cited by this paper
• Evidence for glutamic acid decarboxylase-containing interneurons in the neostriatum.

  1975cited by this paper
• Regional distribution of choline acetyltransferase in the human brain: changes in Huntington's chorea.

  1975cited by this paper
• Decreased muscarinic receptor concentration in post-mortem brain in Huntington's chorea.

  1974cited by this paper
• Bromocriptine in Parkinsonism

  1974cited by this paper
• A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea.

  1974cited by this paper
• The effect of d‐amphetamine on choreiform movement disorders

  1974cited by this paper
• Physostigmine in choreiform movement disorders

  1974cited by this paper
• Brain-decarboxylase activities as indices of pathological change in senile dementia.

  1974cited by this paper
• Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia.

  1974cited by this paper
• Effect of muscarinic agonists on the release of 3H-norepinephrine and 3H-dopamine by potassium and electrical stimulation from rat brain slices.

  1974cited by this paper
• 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid of patients with neurological diseases.

  1974cited by this paper
• Choline acetylase and glutamic acid decarboxylase in Huntington's chorea

  1973cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper
• Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.

  1973cited by this paper
• Use of catechol O‐methyltransferase for the enzyme radiochemical assay of dopamine

  1973cited by this paper
• Pathophysiology of schizophrenia and the striatum.

  1972cited by this paper
• Central cholinergic‐anticholinergic antagonism in Huntington's chorea

  1972cited by this paper
• Amine metabolites in the cerbrospinal fluid in Huntington's chorea.

  1972cited by this paper
• Blockage of caudate-evoked inhibition of neurons in the substantia nigra by picrotoxin.

  1971cited by this paper
• Monosynaptic inhibition of neurons of the substantia nigra by caudato-nigral fibers.

  1971cited by this paper
• Cholinergic and dopaminergic mechanisms in Huntington's chorea.

  1971cited by this paper
• Stereotaxic mapping of the monoamine pathways in the rat brain.

  1971cited by this paper
• 3,4‐Dihydroxyphenylacetic acid and 4‐hydroxy‐3‐methoxyphenylacetic acid in the mouse striatum: a reflection of intra‐ and extra‐neuronal metabolism of dopamine?

  1971cited by this paper
• Role of γ-aminobutyric acid (GABA) in the extrapyramidal motor system

  1971cited by this paper
• Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.

  1971cited by this paper
• Parkinson's Disease: Activity of L-Dopa Decarboxylase in Discrete Brain Regions

  1970cited by this paper
• A pharmacologic analysis of Huntington's chorea.

  1970cited by this paper
• Effect of drugs used in psychoses on cerebral dopamine metabolism

  1970cited by this paper
• Radiochemical micro assays for the determination of choline acetyltransferase and acetylcholinesterase activities.

  1969cited by this paper
• REGIONAL DISTRIBUTION OF γ‐AMINOBUTYRIC ACID (GABA) IN BRAIN OF THE RHESUS MONKEY *

  1968cited by this paper
• Some properties of L-glutamic decarboxylase in mouse brain.

  1963cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Analysis of gene expression related to adrenal physiological functions in Huntington’s disease mouse model

  2025cites this paper
• Efficacy and safety of cholinesterase inhibitors and memantine for cognitive symptoms in patients with Huntington's disease: A systematic review

  2025cites this paper
• Impaired striatal glutathione–ascorbate metabolism induces transient dopamine increase and motor dysfunction

  2024cites this paper
• Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue

  2024cites this paper
• A review of chitosan polysaccharides: Neuropharmacological implications and tissue regeneration.

  2024cites this paper
• Mutant huntingtin expression in the hypothalamus promotes ventral striatal neuropathology

  2023cites this paper
• Beyond Motor Deficits: Environmental Enrichment Mitigates Huntington’s Disease Effects in YAC128 Mice

  2023cites this paper
• Pharmacological Management of Apathy in Dementia

  2022cites this paper
• Striatal Chloride Dysregulation and Impaired GABAergic Signaling Due to Cation-Chloride Cotransporter Dysfunction in Huntington’s Disease

  2022cites this paper
• Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease

  2022cites this paper
• Multiview behavior and neurotransmitter analysis of zebrafish dyskinesia induced by 6PPD and its metabolites.

  2022cites this paper
• Purinergic Signaling in the Pathophysiology and Treatment of Huntington’s Disease

  2021cites this paper
• Mitochondrial Abnormalities and Synaptic Damage in Huntington’s Disease: a Focus on Defective Mitophagy and Mitochondria-Targeted Therapeutics

  2021cites this paper
• Progression of basal ganglia pathology in heterozygous Q175 knock‐in Huntington's disease mice

  2020influential citation
• Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of Hyperkinetic movement associated with Huntington's disease: Pharmacokinetic and brain delivery study.

  2020cites this paper
• Cortical and Striatal Circuits in Huntington’s Disease

  2020cites this paper
• Pro-BDNF knockout causes abnormal motor behaviours and early death in mice.

  2020cites this paper
• Dysfunctional striatal dopamine signaling in Huntington's disease

  2019influential citation
• Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review

  2019cites this paper
• Emotions in action: The relationship between motor function and social cognition across multiple clinical populations

  2018cites this paper
• Disrupted striatal neuron inputs and outputs in Huntington's disease

  2018cites this paper
• Insights into GABAAergic system alteration in Huntington's disease

  2018cites this paper
• NRF 2 ACTIVATION BY DIMERCAPTOPROPANOL ATTENUATES MUTANT HUNTINGTIN TOXICITY ( Spine Title : Dimercaptopropanol attenuates mutant Huntingtin toxicity )

  2018cites this paper
• Huntington’s disease: the coming of age

  2018influential citation
• The Retrieval Deficit Memory Profile in Huntington’s Disease: Reexamining Old Heuristics and Exploring New Ones

  2018cites this paper
• Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

  2017cites this paper
• Alterations of Synaptic Function in Huntington's Disease

  2017cites this paper
• Striatal Vulnerability in Huntington’s Disease: Neuroprotection Versus Neurotoxicity

  2017cites this paper
• Altered behavioral responses to gamma‐aminobutyric acid pharmacological agents in a mouse model of Huntington's disease

  2017cites this paper
• The fate of the brain cholinergic neurons in neurodegenerative diseases.

  2017cites this paper
• Varenicline improves motor and cognitive deficits and decreases depressive‐like behaviour in late‐stage YAC128 mice

  2017cites this paper
• Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington’s disease

  2017cites this paper
• An Overview of the Protective Effects of Chitosan and Acetylated Chitosan Oligosaccharides against Neuronal Disorders

  2017cites this paper
• Epilepsy in Other Neurodegenerative Disorders: Huntington’s and Parkinson’s Diseases

  2017cites this paper
• Cholinergic interneurons in the Q140 knockin mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input

  2016cites this paper
• Impaired Decision Making and Loss of Inhibitory-Control in a Rat Model of Huntington Disease

  2016cites this paper
• Varenicline improves motor and cognitive symptoms in early Huntington’s disease

  2016cites this paper
• Dysregulation of Corticostriatal Connectivity in Huntington’s Disease: A Role for Dopamine Modulation

  2016cites this paper
• Troubles cognitifs et émotionnels dans la maladie de Huntington : Etude chez les patients symptomatiques et présymptomatiques et chez des rats transgéniques, modèles de la maladie de Huntington.

  2016cites this paper
• Targeting the Cholinergic System to Develop a Novel Therapy for Huntington’s Disease

  2016cites this paper
• Compromised Dopaminergic Encoding of Reward Accompanying Suppressed Willingness to Overcome High Effort Costs Is a Prominent Prodromal Characteristic of the Q175 Mouse Model of Huntington's Disease

  2016influential citation
• The Neuropathology of Huntington's Disease.

  2015cites this paper
• Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy.

  2015cites this paper
• Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases

  2015cites this paper
• Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

  2015cites this paper
• Huntington's disease: an update of therapeutic strategies.

  2015cites this paper
• Derivation of enkephalinergic medium spiny neurons from mouse embryonic stem cells

  2015cites this paper
• Mouse Models of Huntington's Disease.

  2015cites this paper
• Noradrenaline transmission reducing drugs may protect against a broad range of diseases.

  2015cites this paper
• L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?

  2015cites this paper
• RETRACTED: Genistein Improves 3-NPA-Induced Memory Impairment in Ovariectomized Rats: Impact of Its Antioxidant, Anti-Inflammatory and Acetylcholinesterase Modulatory Properties

  2015cites this paper
• Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

  2015cites this paper
• Dopamine and Huntington's

  2015cites this paper
• Dopamine and Huntington’s disease

  2015cites this paper
• Quercetin Improves Behavioral Deficiencies, Restores Astrocytes and Microglia, and Reduces Serotonin Metabolism in 3‐Nitropropionic Acid‐Induced Rat Model of Huntington's Disease

  2014cites this paper
• The role of dopamine in Huntington's disease.

  2014cites this paper
• Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?

  2014cites this paper
• Cognitive function in early clinical phase huntington disease after rivastigmine treatment.

  2014cites this paper
• An experimental model for Huntington's chorea?

  2014cites this paper
• Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility

  2013cites this paper
• Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo

  2013cites this paper
• Basal ganglia function in genetic mouse models of Huntington's disease: a circuit-level approach

  2013cites this paper
• Glycogen synthase kinase-3 reduces acetylcholine level in striatum via disturbing cellular distribution of choline acetyltransferase in cholinergic interneurons in rats.

  2013cites this paper
• Endogenous kynurenic acid modulates extracellular glutamate and GABA levels in the rat prefrontal cortex and striatum: in vivo microdialysis studies

  2013cites this paper
• Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review.

  2013cites this paper
• Nigral involvement and nigrostriatal dysfunction in Huntington's disease: evidences from an MRI and SPECT study.

  2013cites this paper
• Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington's disease.

  2013cites this paper
• Structural plasticity of the serotonergic and dopaminergic systems : a multidisciplinary approach

  2012cites this paper
• Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington's disease rats.

  2012cites this paper
• Nrf2 Activation by Dimercaptopropanol Attenuates Mutant Huntingtin Toxicity

  2012cites this paper
• Lessons Learned from the Transgenic Huntington's Disease Rats

  2012cites this paper
• Functional interactions within striatal microcircuit in animal models of Huntington's disease.

  2012influential citation
• The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease.

  2012cites this paper
• Synaptic Dysfunction in Huntington’s Disease

  2011cites this paper
• Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea.

  2011cites this paper
• Seeking Brain Biomarkers for Preventive Therapy in Huntington Disease

  2011cites this paper
• Genetics and neuropathology of Huntington's disease.

  2011cites this paper
• Towards a Novel Treatment of Huntington´s Disease

  2011cites this paper
• Centrality of Striatal Cholinergic Transmission in Basal Ganglia Function

  2011cites this paper
• The Interface between Cytoskeletal Aberrations and Mitochondrial Dysfunction in Alzheimer's Disease and Related Disorders

  2011cites this paper
• Does reduced [(123)I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement?

  2010cites this paper
• Innervation dopaminergique et sérotoninergique du striatum dans les maladies de Parkinson et d'Huntington

  2010cites this paper
• Hyperdopaminergic Status in Experimental Huntington Disease

  2010influential citation
• The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

  2009cites this paper
• Cholinergic Interneuron and Parkinsonism

  2009cites this paper
• Klasická forma Huntingtonovy nemoci manifestovaná asymetrickým parkinsonským syndromem s rigiditou odpovídající na levodopu

  2009cites this paper
• A rodent model of schizophrenia derived from postmortem studies.

  2009cites this paper
• Università degli Studi di Ferrara DOTTORATO DI RICERCA IN " Farmacologia e Oncologia Molecolare "

  2009cites this paper
• Fortschritte in Früh- und Verlaufsdiagnostik bei Morbus Huntington

  2009cites this paper
• High number of striatal dopaminergic neurons during early postnatal development: correlation analysis with dopaminergic fibers

  2008cites this paper
• L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.

  2008cites this paper
• GABAergic circuits in the basal ganglia and movement disorders.

  2007cites this paper
• Dopaminergic neurons intrinsic to the striatum

  2007cites this paper
• Re-emergence of striatal cholinergic interneurons in movement disorders.

  2007cites this paper
• Mitochondrial NAD+‐linked State 3 respiration and complex‐I activity are compromised in the cerebral cortex of 3‐nitropropionic acid‐induced rat model of Huntington’s disease

  2007cites this paper
• Cholinergic neuronal defect without cell loss in Huntington's disease.

  2006cites this paper
• The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.

  2006cites this paper
• Therapeutic Strategies in Huntington's Disease

  2006cites this paper
• Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases

  2005cites this paper
• Imaging in cell-based therapy for neurodegenerative diseases

  2005cites this paper